The diabetes drug dulaglutide—sold commercially as Trulicity—has received an expanded indication for the reduction of major adverse cardiovascular events in adults with type 2 diabetes and established CVD or CV risk factors.

Mount Sinai has launched an Adult Congenital Heart Disease Center at Mount Sinai Heart in New York in an attempt to streamline CHD care throughout the life cycle.

A secondary analysis of the AUGUSTUS trial confirms earlier findings that treating heart patients with the anticoagulant apixaban results in less major bleeding, hospitalization and death than warfarin, a standard-of-care blood thinner.

The FDA has approved bempedoic acid as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia.

Six barbershops in the Toledo, Ohio, area have implemented CV awareness programs that specifically target black men, CBS affiliate WTOL reported Feb. 14.

Researchers on the EXCEL trial have been accused of withholding key mortality data when they first published results suggesting stents were as safe as open-heart surgery in treating patients with left main disease.

An analysis of major cardiology journals in both the U.S. and Europe underlines the stark sex gap in cardiology, revealing that, between 1998 and 2018, there were no women editors-in-chief for U.S. general cardiology journals and only one woman editor-in-chief for a European journal.

The editors of the Journal of the American Heart Association have retracted a study that linked some-day and everyday e-cigarette use to an increased risk of having had a heart attack. The same study alleged the effect of e-cigarettes was comparable to those of conventional cigarettes.